10-AminocamptothecinCAS# 86639-63-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 86639-63-6 | SDF | Download SDF |
| PubChem ID | 104986 | Appearance | Powder |
| Formula | C20H17N3O4 | M.Wt | 363.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | None | ||
| SMILES | CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=CC5=C4)N)O | ||
| Standard InChIKey | MVUUMBZAHAKPKQ-FQEVSTJZSA-N | ||
| Standard InChI | InChI=1S/C20H17N3O4/c1-2-20(26)14-7-16-17-11(5-10-6-12(21)3-4-15(10)22-17)8-23(16)18(24)13(14)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3/t20-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
10-Aminocamptothecin Dilution Calculator
10-Aminocamptothecin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7518 mL | 13.7589 mL | 27.5179 mL | 55.0358 mL | 68.7947 mL |
| 5 mM | 0.5504 mL | 2.7518 mL | 5.5036 mL | 11.0072 mL | 13.7589 mL |
| 10 mM | 0.2752 mL | 1.3759 mL | 2.7518 mL | 5.5036 mL | 6.8795 mL |
| 50 mM | 0.055 mL | 0.2752 mL | 0.5504 mL | 1.1007 mL | 1.3759 mL |
| 100 mM | 0.0275 mL | 0.1376 mL | 0.2752 mL | 0.5504 mL | 0.6879 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 7-Ethyl-10-Hydroxycamptothecin
Catalog No.:BCN2479
CAS No.:86639-52-3
- Xanthiside
Catalog No.:BCN2545
CAS No.:866366-86-1
- 3,4,5-Tricaffeoylquinic acid
Catalog No.:BCN2384
CAS No.:86632-03-3
- PRX-08066 Maleic acid
Catalog No.:BCC1165
CAS No.:866206-55-5
- PRX-08066
Catalog No.:BCC4209
CAS No.:866206-54-4
- Clausine Z
Catalog No.:BCN4414
CAS No.:866111-14-0
- 6-Benzoyl-5,7-dihydroxy-2,2-dimethylchromane
Catalog No.:BCN1326
CAS No.:86606-14-6
- L-745,870 trihydrochloride
Catalog No.:BCC5695
CAS No.:866021-03-6
- Oleuropeic acid 8-O-glucoside
Catalog No.:BCN4025
CAS No.:865887-46-3
- Tideglusib
Catalog No.:BCC4511
CAS No.:865854-05-3
- Isochamaejasmenin B
Catalog No.:BCN3045
CAS No.:865852-48-8
- Chamaejasmenin D
Catalog No.:BCN3046
CAS No.:865852-47-7
- DPPI 1c hydrochloride
Catalog No.:BCC2363
CAS No.:866396-34-1
- Dorsomorphin
Catalog No.:BCC5131
CAS No.:866405-64-3
- 7-Hydroxy-3-prenylcoumarin
Catalog No.:BCN4415
CAS No.:86654-26-4
- [Ala2,8,9,11,19,22,24,25,27,28]-VIP
Catalog No.:BCC5973
CAS No.:866552-34-3
- Yuexiandajisu D
Catalog No.:BCN3774
CAS No.:866556-15-2
- Yuexiandajisu E
Catalog No.:BCN3775
CAS No.:866556-16-3
- (1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutane hydrochloride
Catalog No.:BCC8383
CAS No.:866783-13-3
- BINA
Catalog No.:BCC7849
CAS No.:866823-73-6
- ARL 17477 dihydrochloride
Catalog No.:BCC7647
CAS No.:866914-87-6
- (R)-(+)-2-Amino-3-methyl-1,1-diphenyl-1-butanol
Catalog No.:BCC8394
CAS No.:86695-06-9
- (S)-Methylisothiourea sulfate
Catalog No.:BCC6791
CAS No.:867-44-7
- ROCK inhibitor
Catalog No.:BCC1905
CAS No.:867017-68-3
Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro.[Pubmed:17178889]
Cancer Res. 2006 Dec 15;66(24):11913-21.
A biocompatible polyester dendrimer composed of the natural metabolites, glycerol and succinic acid, is described for the encapsulation of the antitumor camptothecins, 10-hydroxycamptothecin and 7-butyl-10-Aminocamptothecin. The cytotoxicity of the dendrimer-drug complex toward four different human cancer cell lines [human breast adenocarcinoma (MCF-7), colorectal adenocarcinoma (HT-29), non-small cell lung carcinoma (NCI-H460), and glioblastoma (SF-268)] is also reported, and low nmol/L IC(50) values are measured. Cellular uptake and efflux measurements in MCF-7 cells show an increase of 16-fold for cellular uptake and an increase in drug retention within the cell when using the dendrimer vehicle.
Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs.[Pubmed:9140770]
J Chromatogr B Biomed Sci Appl. 1997 Mar 28;691(1):161-71.
The well documented hydrolysis of the alpha-hydroxy-delta-lactone ring moiety in camptothecin and related analogues is routinely monitored using high-performance liquid chromatography (HPLC). Previous HPLC separations of the lactone and carboxylate forms of camptothecins have often required mobile phases containing three to four components; ion-pairing reagent to provide adequate retention of the carboxylate form of the drug; buffer to control the ionic strength and pH of the mobile phase; acetonitrile to control the retention of the lactone form and, in some instances, sodium dodecyl sulfate to reduce peak tailing. Because of the complexity of the mobile phases employed, development of these assays can be a laborious process, requiring re-optimization for each new analogue. In this study, we have developed a simple HPLC methodology for the simultaneous separation of the lactone and carboxylate forms of numerous camptothecin analogues. The mobile phase employed includes only triethylamine acetate (TEAA) buffer and acetonitrile. In this application, triethylamine serves multiple roles; as the ion-pairing reagent, as a masking agent for underivatized silanols and as the major buffer component. By altering only the composition of TEAA buffer with respect to acetonitrile, method development becomes a more streamlined and time efficient process. In this publication, we present the simultaneous separation of the lactone and carboxylate forms of camptothecin and four related analogues, namely, topotecan, GI147211, 10-Aminocamptothecin and the CPT-11-SN-38 drug-metabolite pair. It is proposed that this new mobile phase, consisting of only triethylamine acetate buffer and acetonitrile, can be used for the analysis of the several camptothecin derivatives presently in clinical trials as well as the numerous other analogues in preclinical development.
